There are differences between user groups within each scenario. For the open and delayed access models, HEIs typically experience a smaller gain in access, whether measured as standardised or useful access, reflecting their relatively high (compared to other groups) levels of baseline access. Conversely, groups with lower baseline access experience larger gains. SMEs and Corporations have similar levels of baseline access and experience similar levels of increase in standardised access. In the model, however, this translates into larger gains in access value for SMEs than for Corporations. This is a consequence of the different (lower) level of satisfaction reported in survey responses by SMEs to their levels of access -which means that (given diminishing marginal returns) a given increase in standardised access converts into a larger change in the useful access. We interpret as implying that while neither SMEs or Corporations have high levels of subscribed access, researchers in large Corporations have easier baseline access through alternative routes (document delivery, full-text databases, in-house information services, PPV, etc.).
There are also some variations between users due to subject area differences; these are primarily to do with the assumptions in the Gold and Green scenarios regarding differential take-up by the biomedical research community. (2015) (2016) (2017) (2018) (2019) (2020) (2021) (2022) (2023) (2024) (2025) (2026) (2027) (2028) (2029) (2030) (2031) (2032) (2033) (2034) .
 The Benefit figures presented are the midpoint of the range discussed in the report. The lower bound is based on applying diminishing marginal returns to increases in access, whereas the upper bound does not apply diminishing returns. Therefore, the BCR figure is also a midpoint of the potential range.
 The "£ per SUoA" metric is based on cash costs only  The 10% user efficiency sensitivity (shown for each scenario) applies the efficiency saving to the increases in SUoA only. For example, if the weighted average increase in SUoA is 12%, then user efficiency saving = 10% x 12% = 1.2% saving. 
Green Scenario
£44.2 -£298.7 6.8 £22.1 £0.7 Publisher deposit of biomed articles 25% to 50%
£44.9 £140.2 £195.9 7.5 n/a n/a 10% subscription loss Cost savings to protect margin (-0.1)
£45.0 £54.8 £298.7 7.9 £22.5 £0.7 User efficiency gains in search and access time + 10% efficiency
Green Scenario Sensitivity BCR Range: 3.6 -7.9
Green 'Zero' Scenario 
Delayed Scenario Sensitivity BCR Range: 96.8 -135.5 
Gold (higher APC) Scenario
Gold (higher APC) Scenario Sensitivity BCR Range: 0.6 -3.6 
Gold (lower APC) Scenario
Gold (lower APC) Scenario Sensitivity BCR Range: 1.5 -21.6 
HE Licence extension
HE Licence extension Sensitivity BCR Range: 1.5 -2.7 
NHS Licence extension
NHS Licence extension Sensitivity BCR Range: 2.1 -3.1 The following figures present the UK's annual net costs under each scenario. Each figure is split into two panels:
 Panel A presents the total UK annual net costs, as well as a breakdown by cost type. The three net cost types are: Publication and Distribution steady state net costs; Access Provision steady state net costs; and Transitional Costs (including one-off transaction costs and ongoing system costs).
 Panel B presents the total UK annual net costs, as well as a breakdown by contributor. The two contributors are: Academic Institutions; and Other contributors (including the government, publishers, and other funding groups). 
